Zoetis Inc. (ZTS)
After hours:
| Previous Close | 201.96 |
| Open | 203.11 |
| Bid | 197.67 x 900 |
| Ask | 200.25 x 1000 |
| Day's Range | 200.28 - 203.71 |
| 52 Week Range | 141.41 - 249.27 |
| Volume | |
| Avg. Volume | 1,780,338 |
| Market Cap | 94.781B |
| Beta (5Y Monthly) | 0.66 |
| PE Ratio (TTM) | 48.28 |
| EPS (TTM) | 4.15 |
| Earnings Date | Feb. 15, 2022 |
| Forward Dividend & Yield | 1.30 (0.65%) |
| Ex-Dividend Date | Jan. 19, 2022 |
| 1y Target Est | 248.83 |
- Motley Fool
2 Stocks That Could Turn $250,000 Into $1,000,000 By 2032
Let's look at two excellent companies that could turn $250,000 into $1,000,000 -- that's a compound annual growth rate of 14.87% -- in the next 10 years: Zoetis (NYSE: ZTS) and Spotify (NYSE: SPOT). Zoetis is one of the leading animal health companies in the world. Zoetis boasts 13 products that generate $100 million or more in annual revenue, and its financial results continue to impress.
- Business Wire
Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats
PARSIPPANY, N.J., January 13, 2022--Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia™ to control the pain of osteoarthritis (OA) in cats.
- Reuters
New pain relief for cats with osteoarthritis gets U.S. approval
The U.S. health regulator on Thursday approved Zoetis Inc's once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats. Osteoarthritis breaks down the protective cartilage that cushions the joints, leading to increased friction that causes pain and decreased movement. The drug, Solensia, with the active ingredient frunevetmab, is the first veterinary monoclonal antibody approved by the U.S. Food and Drug Administration.
